Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

25%

1 of 4 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 2
5(100.0%)
5Total
Phase 2(5)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT00040443Phase 2Completed

Efficacy And Safety Of CX516 In Elderly Participants With Mild Cognitive Impairment.

Role: lead

NCT03375021Phase 2Completed

CX717 in the Treatment of Adult ADHD

Role: lead

NCT02735629Phase 2Unknown

Antagonism of Opioid-Induced Respiratory Depression by CX1739 With Preservation of Opioid Analgesia

Role: lead

NCT00235352Phase 2Completed

Trial of Ampakine Added to Clozapine, Olanzapine or Risperidone in Patients With Schizophrenia

Role: collaborator

NCT00054730Phase 2Completed

Effects of CX516 on Functioning in Fragile X Syndrome and Autism

Role: lead

All 5 trials loaded